Medigene AG (MDGEF)
USD 2.59
(0.0%)
USD 2.59
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -15.02 Million EUR | -214.39% |
| 2022 | 13.13 Million EUR | 302.39% |
| 2021 | -6.49 Million EUR | 69.81% |
| 2020 | -21.5 Million EUR | -25.78% |
| 2019 | -17.09 Million EUR | 19.0% |
| 2018 | -21.1 Million EUR | -33.41% |
| 2017 | -15.82 Million EUR | 12.2% |
| 2016 | -18.02 Million EUR | -36.47% |
| 2015 | -9.47 Million EUR | -302.07% |
| 2014 | -3.3 Million EUR | 56.45% |
| 2013 | -7.93 Million EUR | 23.27% |
| 2012 | -12.68 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.09 Million EUR | 0.0% |
| 2023 Q4 | -4.23 Million EUR | -1.47% |
| 2023 Q3 | -4.17 Million EUR | -1.42% |
| 2023 FY | - EUR | -214.39% |
| 2023 Q1 | -3.35 Million EUR | -138.55% |
| 2023 Q2 | -4.11 Million EUR | -22.86% |
| 2022 Q2 | -1.77 Million EUR | -122.99% |
| 2022 Q3 | 8.69 Million EUR | 590.82% |
| 2022 Q4 | 8.69 Million EUR | 0.0% |
| 2022 FY | - EUR | 302.39% |
| 2022 Q1 | 7.7 Million EUR | 413.68% |
| 2021 FY | - EUR | 69.81% |
| 2021 Q3 | -643 Thousand EUR | 86.1% |
| 2021 Q4 | -2.45 Million EUR | -281.96% |
| 2021 Q1 | -2.22 Million EUR | 76.3% |
| 2021 Q2 | -4.62 Million EUR | -107.68% |
| 2020 Q2 | -11.32 Million EUR | -100.04% |
| 2020 Q1 | -5.66 Million EUR | -38.87% |
| 2020 Q4 | -9.39 Million EUR | -50.42% |
| 2020 Q3 | -6.24 Million EUR | 44.84% |
| 2020 FY | - EUR | -25.78% |
| 2019 Q1 | -5.21 Million EUR | 37.92% |
| 2019 Q4 | -4.07 Million EUR | 27.02% |
| 2019 Q2 | -3.53 Million EUR | 32.2% |
| 2019 FY | - EUR | 19.0% |
| 2019 Q3 | -5.58 Million EUR | -58.12% |
| 2018 Q2 | -3.67 Million EUR | 5.09% |
| 2018 Q3 | -5.16 Million EUR | -40.74% |
| 2018 FY | - EUR | -33.41% |
| 2018 Q4 | -8.39 Million EUR | -62.47% |
| 2018 Q1 | -3.86 Million EUR | 31.12% |
| 2017 FY | - EUR | 12.2% |
| 2017 Q4 | -5.61 Million EUR | -66.47% |
| 2017 Q3 | -3.37 Million EUR | 13.45% |
| 2017 Q2 | -3.89 Million EUR | -27.15% |
| 2017 Q1 | -3.06 Million EUR | 7.32% |
| 2016 Q2 | -3.09 Million EUR | 4.69% |
| 2016 Q3 | -5.07 Million EUR | -64.21% |
| 2016 Q1 | -3.24 Million EUR | -10.91% |
| 2016 FY | - EUR | -36.47% |
| 2016 Q4 | -3.3 Million EUR | 34.81% |
| 2015 Q2 | -2.21 Million EUR | -8.23% |
| 2015 FY | - EUR | -302.07% |
| 2015 Q4 | -2.92 Million EUR | -25.45% |
| 2015 Q3 | -2.33 Million EUR | -5.43% |
| 2015 Q1 | -2.04 Million EUR | -271.89% |
| 2014 Q3 | -1.64 Million EUR | -831.82% |
| 2014 Q4 | 1.18 Million EUR | 172.44% |
| 2014 Q2 | -176 Thousand EUR | 93.37% |
| 2014 Q1 | -2.65 Million EUR | -86.12% |
| 2014 FY | - EUR | 56.45% |
| 2013 Q4 | -1.42 Million EUR | 21.38% |
| 2013 Q3 | -1.81 Million EUR | 8.98% |
| 2013 Q2 | -1.99 Million EUR | 13.15% |
| 2013 FY | - EUR | 23.27% |
| 2013 Q1 | -2.29 Million EUR | 27.36% |
| 2012 Q3 | -2.09 Million EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q4 | -3.16 Million EUR | -51.17% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 78.846% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -153.453% |
| SQZ Biotechnologies Company | -64.14 Million USD | 76.572% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 13.489% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 115.98% |
| Mesoblast Limited | -62.38 Million USD | 75.914% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -878.289% |
| Genus plc | 73.7 Million USD | 120.389% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -127.285% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -323.654% |
| Marizyme, Inc. | -34.28 Million USD | 56.166% |
| ContraFect Corporation | -64.99 Million USD | 76.881% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -71.306% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -232.001% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -971.973% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -468.247% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -546.651% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2800.708% |
| Accustem Sciences Inc. | -3.74 Million USD | -301.103% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 68.841% |
| EV Biologics, Inc. | -1.26 Million USD | -1085.906% |
| Q BioMed Inc. | -617.62 Thousand USD | -2333.018% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 520.689% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2276.163% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -557.784% |
| Biomind Labs Inc. | -1.03 Million USD | -1352.517% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 252.141% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -109.837% |
| Skye Bioscience, Inc. | -13.54 Million USD | -10.92% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -910.278% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -60008.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -286.863% |
| IMV Inc. | -35.52 Million USD | 57.698% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 5.31% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -500.609% |
| GB Sciences, Inc. | -1.41 Million USD | -958.325% |
| Alpha Cognition Inc. | -9.7 Million USD | -54.828% |
| HST Global, Inc. | -5303.00 USD | -283267.905% |
| CSL Limited | 4.78 Billion USD | 100.314% |
| Halberd Corporation | -74.27 Thousand USD | -20130.482% |
| Enzolytics Inc. | -2.12 Million USD | -608.143% |
| Resverlogix Corp. | -11.74 Million USD | -27.976% |
| Affymax, Inc. | -14.29 Million USD | -5.121% |
| SYBLEU INC | -141.57 Thousand USD | -10514.462% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -390.595% |
| argenx SE | -216.02 Million USD | 93.044% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 72.846% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1334.758% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -902.531% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 4066.54% |
| AVAX Technologies, Inc. | -6.11 Million USD | -145.835% |
| Zenith Capital Corp. | -8.6 Million USD | -74.611% |
| Genscript Biotech Corporation | -248.71 Million USD | 93.958% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -86157.965% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -514.234% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -8436.887% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 62.088% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -419.547% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1336.187% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 223583.046% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -758.686% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -682.285% |
| BioStem Technologies, Inc. | -7.55 Million USD | -98.937% |
| ONE Bio Corp. | 13.61 Million USD | 210.387% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -8198.175% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -630.53% |
| Agentix Corp. | -1.37 Million USD | -995.457% |
| LadRx Corporation | 412.28 Thousand USD | 3744.826% |
| Cell Source, Inc. | -4.27 Million USD | -251.712% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3992.086% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1125.065% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1503.823% |
| NovAccess Global Inc. | -1.03 Million USD | -1352.169% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 269.724% |
| Itoco Inc. | -1.86 Million USD | -704.015% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -3858.432% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1246.505% |
| Kadimastem Ltd | -2.62 Million USD | -472.592% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -6183.504% |
| CytoDyn Inc. | -18.02 Million USD | 16.651% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -18914.539% |
| Mobile Lads Corp. | -2.24 Million USD | -570.501% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -122780.039% |
| Qrons Inc. | -40.08 Thousand USD | -37391.58% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2994.025% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2949.082% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1480.126% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1314.958% |
| International Stem Cell Corporation | 202 Thousand USD | 7539.109% |
| Bioxytran, Inc. | -3.82 Million USD | -293.362% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -28446.733% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -510.374% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 58.106% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -33293.333% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -448.831% |
| Neutra Corp. | -181.24 Thousand USD | -8190.896% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 25.458% |
| PureTech Health plc | -11.62 Million USD | -29.242% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 25.453% |
| IXICO plc | -707 Thousand USD | -2025.46% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -95.537% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 68.918% |
| CSL Limited | 4.73 Billion USD | 100.317% |
| Cellectis S.A. | -92.63 Million USD | 83.778% |